PMA and Doxorubicin Decrease Viability, MTT Activity and Expression of CD10 Marker on NALM-1 Leukemic Cells

Abstract

PMA (10, 20 ng/ml) and doxorubicin (5-20 ng/ml) decreased the viability and MTT-activity of NALM-1 pre-B leukemic cells (3 days' treatment). Further, CD10 was downregulated, suggesting that PMA and doxorubicin induced differentiation of NALM-1 cells. However, PMA did not alter expression of B cell markers CD20 and of mIgM. In contrast to PMA, another differentiation agent ATRA did not alter CD10 expression on NALM-1 cells but affected viability after 6 days (5, 10 ng/ml). The data in this study are the first evidence that PMA and doxorubicin inhibited viability and MTT activity and induced partial differentiation, by decreasing CD10 on NALM-1 cells.

Reversible Cell‐Specific Drug Delivery with Aptamer‐Functionalized Liposomes

“…After the addition of various formulations of liposomes, the cells were incubated for 5 h and then washed with PBS (2×100 μL well −1 ). The cells were further incubated in prewarmed growth medium for 48 h or 96 h. The cell viabilities were assessed colorimetrically by following the standard MTT protocol 55…”

Reversible Cell‐Specific Drug Delivery with Aptamer‐Functionalized Liposomes

“…The cells were further incubated in prewarmed growth medium for 48 h or 96 h. The cell viabilities were assessed colorimetrically by following the standard MTT protocol. [55]…”

Controlled Synthesis of Camptothecin−Polylactide Conjugates and Nanoconjugates

“…The cells were incubated for 72 h in a 5% CO 2 incubator at 37°C. The standard MTT assay protocols were followed thereafter (20). …”